Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Abpro CorpABP · Entity 166815 | Director | May 10, 2018 | May 11, 2018 |
| Cellectar Biosciences, Inc.CLRB · Entity 7572 | Director | July 07, 2026 | July 09, 2026 |
| Conformis IncCFMS · Entity 109987 | INTERIM CFO & INTERIM TREAS | October 23, 2019 | October 28, 2019 |
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | January 02, 2025 | January 03, 2025 |
| ImmunityBio, Inc.NK · Entity 3618 | Director | August 11, 2020 | August 13, 2020 |
| Invivyd, Inc.IVVD · Entity 721 | Interim CFO | October 13, 2022 | October 13, 2022 |
| Lite Strategy, Inc.LITS · Entity 7396 | Director | November 14, 2025 | November 18, 2025 |
| Renovacor, Inc.RCOR · Entity 114644 | Chief Financial Officer | March 28, 2022 | March 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Abpro Corp
Report date May 10, 2018 · Filed May 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,089 |
Reported balance
Holding disclosure · report date 2018-05-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 25,089 F1: This security represents restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. 25% of the RSU shall vest on August 31, 2018; the remainder will vest in equal monthly installments over the 36 month period following August 31, 2018, subject to continuous service by the Reporting Person to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This security represents restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. 25% of the RSU shall vest on August 31, 2018; the remainder will vest in equal monthly installments over the 36 month period following August 31, 2018, subject to continuous service by the Reporting Person to the Issuer on each such date.
Cellectar Biosciences, Inc.
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-07-07 | Direct | 25,000 |
Reported balance
After 2026-07-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-07 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.
Conformis Inc
Report date October 23, 2019 · Filed October 28, 2019
This filing explicitly reported no securities owned.
Cue Biopharma, Inc.
Report date January 02, 2025 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2035-01-01 | Direct | 24,400 |
Reported balance
After 2025-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 24,400 · Balance 24,400 F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2: This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2: This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date.
ImmunityBio, Inc.
Report date August 11, 2020 · Filed August 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,235 |
Ending reported balance
After 2020-08-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-08-11 · Sale · Disposed 50,000 · Balance 124,535 F1: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person. F2: Represents the weighted average share price of an aggregate total of 50,000 shares sold in the price range of $9.89 to $10.7275 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2020-08-11 · Sale · Disposed 10,000 · Balance 114,535 F1: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person. F3: Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $9.94 to $10.0301 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2020-08-11 · Sale · Disposed 5,300 · Balance 109,235 F1: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person. F4: Represents the weighted average share price of an aggregate total of 5,300 shares sold in the price range of $10.50 to $11.07 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person.
F2: Represents the weighted average share price of an aggregate total of 50,000 shares sold in the price range of $9.89 to $10.7275 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $9.94 to $10.0301 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Represents the weighted average share price of an aggregate total of 5,300 shares sold in the price range of $10.50 to $11.07 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Invivyd, Inc.
Report date October 13, 2022 · Filed October 13, 2022
This filing explicitly reported no securities owned.
Lite Strategy, Inc.
Report date November 14, 2025 · Filed November 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2035-11-14 | Direct | 55,000 |
Reported balance
After 2025-11-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-14 · Grant · Acquired 55,000 · Balance 55,000 F2: Received as compensation for service on the Board. F1: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026.
F2: Received as compensation for service on the Board.
Renovacor, Inc.
Report date March 28, 2022 · Filed March 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2032-03-28 | Direct | 155,325 |
Reported balance
After 2022-03-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-28 · Grant · Acquired 155,325 · Balance 155,325 F1: The stock option will vest and become exercisable in full on March 28, 2026, with 25% vesting on March 28, 2023, and the remainder vesting in equal monthly installments for the remaining 36 months, subject to the continuous service of the Reporting Person on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest and become exercisable in full on March 28, 2026, with 25% vesting on March 28, 2023, and the remainder vesting in equal monthly installments for the remaining 36 months, subject to the continuous service of the Reporting Person on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 30,680 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2031-05-31 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 168,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 01:10 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001104659-26-082016 · tm2620095-8_4seq1.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2036-07-07 F1 · derivative.exercise_date: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 23:36 UTC | Lite Strategy, Inc. LITS · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $2.02 | Not disclosed |
DisclosureSEC source: 0001193125-25-286568 · ownership.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-11-14 F2 · price: Received as compensation for service on the Board. F1 · derivative.exercise_date: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026. Read SEC document |
| July 15, 2025 Filed Jul 18, 2025 01:33 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0000929638-25-002634 · form4.xml · derivative · entry 2 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-07-15 F1 · security: Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:03 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001104659-25-014740 · tm256830-3_4seq1.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-02-14 F1 · derivative.exercise_date: This option shall vest in full on February 14, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000950170-25-001106 · ownership.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2035-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 21:00 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001104659-24-072880 · tm2417520-2_4seq1.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-12-22 F1 · date: This option was contingently granted on December 22, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024. F2 · derivative.exercise_date: This option shall vest in full on December 22, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:02 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000950170-24-001829 · ownership.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2034-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date. Read SEC document |
| September 29, 2023 Filed Oct 12, 2023 23:41 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0000929638-23-002773 · form4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-09-29 F1 · derivative.exercise_date: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024. Read SEC document |
| June 28, 2023 Filed Jun 28, 2023 22:24 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001104659-23-075938 · tm2320030-2_4seq1.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,650 Underlying: Common Stock · 25,000 shares Expires 2033-06-28 F1 · derivative.exercise_date: This stock option shall vest in full on June 28, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:08 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-23-001776 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 3, 2023. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:27 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 87.5 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0000899243-22-025712 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2032-07-05 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| June 24, 2022 Filed Aug 1, 2022 22:00 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 7,800 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001104659-22-084835 · tm2222253-2_4seq1.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2032-06-24 F1 · derivative.exercise_price: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F1 · shares: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F2 · derivative.exercise_date: This stock option shall vest in full on June 24, 2023, subject to the reporting person's continued service through the applicable vesting date. F1 · derivative.underlying_shares: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F1 · balance_after: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 23:38 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantOption · Derivative | 155,325 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001062993-22-008797 · form4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,325 Underlying: Common Stock · 155,325 shares Expires 2032-03-28 F1 · derivative.exercise_date: The stock option will vest and become exercisable in full on March 28, 2026, with 25% vesting on March 28, 2023, and the remainder vesting in equal monthly installments for the remaining 36 months, subject to the continuous service of the Reporting Person on such vesting date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:22 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0000899243-22-001046 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 15:00 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 168,000 | Not disclosed Strike: $8.35 | Not disclosed |
DisclosureSEC source: 0001209191-21-065705 · doc4.xml · derivative · entry 2 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 168,000 shares Expires 2031-05-31 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 15:00 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerCommon Stock | 30,680 | $8.50 | $260,780.00 |
DisclosureSEC source: 0001209191-21-065705 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2 · shares: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:01 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock | 19,417 | $1.04 | $20,244.16 |
DisclosureSEC source: 0001104659-21-113416 · tm2127071-1_4seq1.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,417 Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 22:58 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001209191-21-045655 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:03 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 78,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001104659-21-088836 · tm2120855-3_4seq1.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: This option shall vest on the first anniversary of the date of grant. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 168,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001209191-21-037641 · doc4.xml · derivative · entry 2 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,000 Underlying: Common Stock · 168,000 shares Expires 2031-05-31 F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest on the one-year anniversary of May 17, 2021 (the "Vesting Commencement Date"), and 1/48th of the shares subject to the option shall vest each month following the one-year anniversary of the Vesting Commencement Date, so that all of the shares subject to the options shall be vested four years after the Vesting Commencement Date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037641 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,680 F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 17:08 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | SaleCommon Stock | 25,000 | $4.03 | $100,625.00 |
DisclosureSEC source: 0001209191-21-013670 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0000899243-21-000710 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:31 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 5,300 | $10.77 | $57,064.57 |
DisclosureSEC source: 0001209191-20-046606 · doc4.xml · nonDerivative · entry 3 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,235 F1 · kind: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person. F4 · price: Represents the weighted average share price of an aggregate total of 5,300 shares sold in the price range of $10.50 to $11.07 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:31 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 10,000 | $9.98 | $99,787.00 |
DisclosureSEC source: 0001209191-20-046606 · doc4.xml · nonDerivative · entry 2 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,535 F1 · kind: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person. F3 · price: Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $9.94 to $10.0301 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:31 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 50,000 | $10.22 | $511,200.00 |
DisclosureSEC source: 0001209191-20-046606 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,535 F1 · kind: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person. F2 · price: Represents the weighted average share price of an aggregate total of 50,000 shares sold in the price range of $9.89 to $10.7275 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 17:15 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0000899243-20-018615 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-07-02 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 20:21 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001104659-20-076870 · tm2023456d2_4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-24 F1 · derivative.exercise_date: This option grant shall vest over a period of three years from the grant date, with one-third vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 22:22 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001209191-20-036034 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 10, 2021 or the date immediately preceding the 2021 annual meeting of stockholders. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:52 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002057 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 17:56 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | PurchaseCommon Stock | 62,500 | $1.60 | $100,000.00 |
DisclosureSEC source: 0001209191-19-061473 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 19:32 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-19-040977 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-07-01 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:32 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 6,500 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001144204-19-031009 · tv523610_4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2029-06-13 F1 · derivative.exercise_date: Options vest on the one year anniversary of the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 20:41 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantCommon Stock | 92,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035583 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,535 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · shares: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of June 6, 2020 or the date immediately preceding the 2020 annual meeting of stockholders. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 23:36 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001324 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 23:49 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001144204-18-053879 · tv504844_form4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-10-12 F1 · derivative.exercise_date: This option grant was divided into a definitive grant of 6,150 shares, which vest in equal monthly installments over a seven month period from the grant date, and a contingent grant of 6,850 shares, which are subject to the following conditions: (i) approval by Cellectar's stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation's 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the contingent grant shall vest immediately upon such stockholder approval. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 21:26 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001209191-18-042667 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-07-12 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 20:17 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001209191-18-039658 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-06-26 F1 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning December 26, 2018. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:16 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantCommon Stock | 27,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036923 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,943 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · shares: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of June 7, 2019 or the date immediately preceding the 2019 annual meeting of stockholders. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 18:12 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantOptions to purchase shares of common stock · Derivative | 33,333 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013268 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock, par value $0.00000002 per share · 33,333 shares Expires 2028-02-22 F1 · derivative.exercise_date: 20,000 options will vest ratably each month beginning March 1, 2018 over thirty-six months, and 13,333 of the options will vest ratably each month beginning March 1, 2018 over four months. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 21:35 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantCommon Stock | 54,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053488 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,621 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, one thirty-sixth (1/36th) of the RSUs subject to the award will vest monthly over thirty six (36) months, such that the award will be fully vested on September 18, 2020. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 22:04 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001144204-17-030682 · v468271_4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: Options vest in equal annual increments over a period of three years from the date of grant. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 20:24 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionStock option (right to buy) · Derivative | 3,000 | $0.00 Strike: $7.89 | $0.00 |
DisclosureSEC source: 0001209191-17-022762 · doc4.xml · derivative · entry 3 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,300 Underlying: Common Stock · 3,000 shares Expires 2023-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vest one year after May 20, 2013, with 1/48th of the shares vesting monthly thereafter over the next 3 years. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 20:24 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 3,000 | $23.00 | $69,000.00 |
DisclosureSEC source: 0001209191-17-022762 · doc4.xml · nonDerivative · entry 2 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,777 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted December 20, 2016. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 20:24 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionCommon Stock | 3,000 | $7.89 | $23,658.30 |
DisclosureSEC source: 0001209191-17-022762 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.89 | $0.00 |
DisclosureSEC source: 0001209191-17-016741 · doc4.xml · derivative · entry 4 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,300 Underlying: Common Stock · 30,000 shares Expires 2023-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vest one year after May 20, 2013, with 1/48th of the shares vesting monthly thereafter over the next 3 years. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 600 | $20.42 | $12,250.02 |
DisclosureSEC source: 0001209191-17-016741 · doc4.xml · nonDerivative · entry 3 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,777 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted December 20, 2016. F4 · price: The weighted average sale price for the transaction reported was $20.4167, and the range of prices were between $20.41 and $20.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 32,834 | $19.96 | $655,429.02 |
DisclosureSEC source: 0001209191-17-016741 · doc4.xml · nonDerivative · entry 2 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,377 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted December 20, 2016. F3 · price: The weighted average sale price for the transaction reported was $19.9619, and the range of prices were between $19.41 and $20.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionCommon Stock | 30,000 | $7.89 | $236,583.00 |
DisclosureSEC source: 0001209191-17-016741 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 680 shares of Common Stock that were acquired by the Reporting Person on November 20, 2015 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 21:38 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001209191-16-156531 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-12-19 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest one year after December 20, 2016; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of December 20, 2016, so that all of the shares subject to the option shall be vested four (4) years after December 20, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.